PRTODAY / NewswireToday Free press release distribution service network

More news: Research
Written by / Agency / Source: Becton, Dickinson and Company

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Teva Pharmaceuticals Confirms the BD PhaSeal™ System is Compatible with Chemotherapy Drug Treanda® Injection - FDA Updates March 2015 Safety Alert on CSTD Compatibility for Treanda® Injection - BD.com
Teva Pharmaceuticals Confirms the BD PhaSeal™ System is Compatible with Chemotherapy Drug Treanda® Injection

 

NewswireToday - /newswire/ - Franklin Lakes, NJ, United States, 2015/09/29 - FDA Updates March 2015 Safety Alert on CSTD Compatibility for Treanda® Injection - BD.com. NYSE: BDX

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BD (Becton, Dickinson and Company), notified customers that the U.S. Food and Drug Administration (FDA) has updated its March 2015 Safety Alert based on Teva Pharmaceuticals’ (Teva) findings which include that the BD PhaSeal™ System is the only closed system drug transfer device (CSTD) compatible with the chemotherapy drug, Treanda® Injection (bendamustine HCl) based on the testing performed by Teva from February through June 2015.

Consistent with all previous BD PhaSeal System testing, Teva’s independent studies confirmed the compatibility of the BD PhaSeal CSTD consisting of: BD PhaSeal Protector (P14), BD PhaSeal Injector (N35), and BD PhaSeal Infusion Adapter (C100). The raw materials used in the system are chosen for their chemical resistance and these products do not contain polycarbonate or ABS in the fluid path material shown to interact with hazardous drugs that contain the solvent N, N-Dimethylacetamide. In addition, Teva also identified the BD PhaSeal Secondary Set (C60) is compatible for IV administration of Treanda Injection.

Treanda is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) and bendamustine is recognized by the National Comprehensive Cancer Network (NCCN) as a first line therapy for CLL. The BD PhaSeal System is not contraindicated for any known hazardous drugs, including those that contain N, N-dimethylacetamide as a solvent.

“BD is committed to providing health care workers with the proper protection required to handle hazardous drugs that can help save the lives of patients in need,” said Lynne Kelley, MD, FACS, Vice President, Worldwide Medical Affairs, BD Medication & Procedural Solutions, BD Medical. “We are proud to offer one of the most comprehensive portfolios to empower protection of healthcare workers from hazardous drug exposure. Our goal is to help ensure that every patient around the world receives the necessary medication required for their specific treatment plan, without jeopardizing the health of the hospital workers who handle these hazardous drugs.”

BD shares the FDA’s focus on educating health care providers about the proper use of its products to ensure safe medication practices and the safe handling of hazardous drugs. Earlier this month, Teva Pharmaceuticals issued a letter to health care providers summarizing the compatibility results from their internal testing, which was immediately followed by an updated Safety Alert from the FDA confirming the compatibility between Treanda Injection and the BD PhaSeal System the only CSTD verified by Teva to be compatible with its chemotherapy drug.

About BD

BD (bd.com) is a leading medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and evolving health needs. Our innovative solutions are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology and respiratory care; advancing cellular research and applications; enhancing the diagnosis of infectious diseases and cancers; and supporting the management of diabetes. We are more than 45,000 associates in 50 countries who strive to fulfill our purpose of “Helping all people live healthy lives” by advancing the quality, accessibility, safety and affordability of healthcare around the world. In 2015, BD welcomed CareFusion and its products into the BD family of solutions.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Becton, Dickinson and Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!


Teva Pharmaceuticals Confirms the BD PhaSeal™ System is Compatible with Chemotherapy Drug Treanda® Injection

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

BD PhaSeal™ System | Teva Pharmaceuticals
Publisher Contact: Matt Coppola - BD.com 
201-847-7370 matthew_r_coppola[.]bd.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Becton, Dickinson and Company securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Becton, Dickinson and Company / Company Profile


Read Research Most Recent Related Newswires:

DSM Announces Exclusive Partnership with Nanjing Cosmos Chemical Co., Ltd and Plans to Continue Expansion in UV Filters
DSM Launches New Enzyme Solutions At IFT17 to Improve Softness and Moistness of Gluten-free Bread
DSM and Evonik Select Nebraska for Production of Breakthrough Omega-3
Phasor to Develop Next Generation Electronically Steerable Antenna Featuring DSM Dyneema’s Advanced Radome Solution
DSM’s Delvotest® T Antibiotic Residue Test for Milk Validated by Finnish Food Safety Authority
Royal DSM to Make Equity Investment in Amyris with the Purpose of Establishing A Long-term Relationship
DSM Unveils New Beauty Active At NYSCC Suppliers’ Day
Iridea Bio - A New Sustainable Paint Made with DSM’s Decovery® Plant-based Resin
DSM to Showcase A Wide Range of Innovative Composite Solutions
DSM’s New Protective Delvo®Guard Cultures Reduce Food Waste in Dairy
DSM and Evonik Establish Joint Venture for Omega-3 Fatty Acids from Natural Marine Algae for Animal Nutrition
DSM Introduces Dyneema Purity® Black Fiber - The First Black Medical-grade UHMWPE Fiber
Research by German Wildau Technical University Confirms Long-term Performance of Dyneema® Soft Ballistics for Use in Bullet Resistant Vests
DSM Dyneema Wins Significant Patent Case in Israel
Actamax™ Submits IDE to FDA for Pivotal Study on Novel Sprayable Adhesion Barrier Device

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)